Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

CLLS
Cellectis S.A.
stock NASDAQ ADR

At Close
Jun 11, 2026 3:59:53 PM EDT
3.11USD-2.201%(-0.07)74,677
2.56Bid   3.71Ask   1.15Spread
Pre-market
Jun 11, 2026 8:09:30 AM EDT
3.12USD-1.887%(-0.06)1,512
After-hours
Jun 11, 2026 4:00:30 PM EDT
3.09USD-0.643%(-0.02)4,601
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 10, 2022
04:33PM EST  Cellectis' Licensed Partner, Allogene Therapeutics, Announces Removal Of FDA Clinical Hold On Their Clinical Trials   Benzinga
04:30PM EST  Allogene reported that Chromosomal Abnormality Was Not the Result of TALEN Gene Editing or Allogenes Manufacturing Process   GlobeNewswire Inc
Jan 6, 2022
10:06AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022   Benzinga
05:51AM EST  Wells Fargo Downgrades Cellectis to Equal-Weight, Announces $16 Price Target   Benzinga
Jan 5, 2022
08:20AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets   Benzinga
Jan 4, 2022
04:32PM EST  Cellectis Offers Update On 2022 Expected Milestones For Its Pipeline   Benzinga
04:30PM EST  Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, reported business objectives for its products pipeline and in-house manufacturing for 2022.   GlobeNewswire Inc
Dec 14, 2021
06:36AM EST  Cellecttis Granted U.S. Patent #11,198,856 'Method for the generation of compact tale-nucleases and uses thereof'   Benzinga
Dec 12, 2021
04:56PM EST  The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More   Benzinga
Dec 11, 2021
10:07AM EST  Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in   GlobeNewswire Inc
Dec 6, 2021
06:07AM EST  The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More   Benzinga
Nov 30, 2021
04:51PM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021   Benzinga
04:44PM EST  JMP Securities Initiates Coverage On Cellectis with Market Outperform Rating, Announces Price Target of $20   Benzinga
Nov 19, 2021
07:09AM EST  Cytovia, Cellectis Expand Collaboration On Gene-Edited Cancer Platform In China   Benzinga
Nov 18, 2021
04:32PM EST  Cytovia And Cellectis Expand Their TALEN Gene-Edited iNK Partnership To Enable Broader Collaboration In China   Benzinga
04:30PM EST  Cytovia and Cellectis Expand Their TALEN Gene-Edited   GlobeNewswire Inc
Nov 12, 2021
08:24AM EST  Cellectis Presents First Preclinical Data On UCARTMESO, An Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin To Treat Solid Tumors At Annual Meeting Of Society For Immunotherapy Of Cancer   Benzinga
08:10AM EST  Cellectis Presents First Preclinical Data on UCARTMESO, an   GlobeNewswire Inc
Nov 5, 2021
09:33AM EDT  Cellectis Q3 EPS $(0.71) Beats $(0.83) Estimate, Sales $10.83M Miss $11.14M Estimate   Benzinga
Nov 4, 2021
09:30AM EDT  Cellectis Announces Release Of Abstracts At ASH Showcasing Updated Preliminary Clinical Data From BALLI-01 Study And First Preclinical Data From TALGlobin01   Benzinga
05:00AM EDT  Earnings Scheduled For November 4, 2021   Benzinga
Oct 19, 2021
04:31PM EDT  Cellectis Presents Initial Preclinical Data On 2 Novel Gene Therapies For Patients With RAG1 Severe Combined Immunodeficiency (SCID) And Hyper IgE syndrome At ESGCT 2021   Benzinga
04:30PM EDT  Cellectis Presents Initial Preclinical Data on Two Novel Gene   GlobeNewswire Inc
Oct 12, 2021
04:36PM EDT  Cellectis To Present Preclinical Data On UCARTMESO Supporting Anti-Tumor Activity At Society For Immunotherapy Of Cancer (SITC) 36th Annual Meeting Nov. 10-14   Benzinga
04:35PM EDT  Cellectis to Present Preclinical Data on UCARTMESO Supporting   GlobeNewswire Inc
Oct 11, 2021
06:08AM EDT  The following are some of the stocks making big moves in Monday's pre-market trading (as of 5.55 A.M. EDT).   RTTNews
Oct 8, 2021
02:36PM EDT  Mid-Afternoon Market Update: Dow Surges 80 Points; ChemoCentryx Shares Spike Higher   Benzinga
12:30PM EDT  Mid-Day Market Update: Crude Oil Rises 2%; Allogene Therapeutics Shares Plunge   Benzinga
11:52AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 8, 2021   Benzinga
10:11AM EDT  Mid-Morning Market Update: Markets Edge Higher; US Economy Adds 194,000 Jobs In September   Benzinga
09:11AM EDT  10 Biggest Price Target Changes For Friday   Benzinga
08:00AM EDT  Baird Downgrades Cellectis to Neutral, Lowers Price Target to $10   Benzinga
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Aug 26, 2021
04:35PM EDT  Cellectis S.A. (NASDAQ: CLLS EURONEXT GROWTH: ALCLS) (the Company), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for monogenic diseases, today announced that management plans to participate in five virtual investor conferences.   GlobeNewswire Inc
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 5, 2021
06:19PM EDT  Cellectis Q2 EPS $(0.88) Misses $(0.73) Estimate, Sales $14.62M Beat $11.10M Estimate   Benzinga
04:08AM EDT  Earnings Scheduled For August 5, 2021   Benzinga
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jun 15, 2021
07:24AM EDT  Cellectis Unveils Four Additional Preclinical Candidates For Solid Tumors   Benzinga
Jun 14, 2021
04:33PM EDT  Cellectis Highlights Innovation Days Event   Benzinga
04:30PM EDT  Four new product candidates under pre-clinical development announced; UCART20x22; the first allogeneic bi-specific CAR-T cell targetingB-cell malignancies, and three additional product candidates for solid tumors UCARTMESO (targeting Mesothelin),UCARTMUC1 (targeting Mucin 1), UCARTFAP (targeting Cancer Associated Fibroblasts)   GlobeNewswire Inc
Jun 4, 2021
09:39AM EDT  The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact   Benzinga
Jun 2, 2021
02:30AM EDT  Cellectis S.A. held its Annual Shareholders General Meeting (Euronext Growth: ALCLS Nasdaq: CLLS) on June 1, 2021 at its head office in Paris, France.   GlobeNewswire Inc
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 11, 2021
04:46PM EDT  Cellectis And Sanofi Enter Partnership And Supply Agreement For Alemtuzumab; Financial Details Not Disclosed   Benzinga
04:30PM EDT  Cellectis and Sanofi partner on alemtuzumab as   GlobeNewswire Inc
May 6, 2021
05:45PM EDT  Cellectis Q1 EPS $(0.26) Down From $0.57 YoY, Sales $27.97M Down From $51.91M YoY   Benzinga
Apr 28, 2021
10:28AM EDT  Guggenheim Downgrades Cellectis to Neutral   Benzinga
Apr 26, 2021
04:39PM EDT  Cellectis Annual Shareholders   GlobeNewswire Inc
Apr 9, 2021
02:30AM EDT  Cellectis Completes Sale of $47 million through its ATM program   GlobeNewswire Inc
Mar 30, 2021
08:06AM EDT  The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings   Benzinga
Mar 29, 2021
04:51PM EDT  Cellectis Establishes $125M At-The-Market Offering   Benzinga
04:50PM EDT  Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq   GlobeNewswire Inc
Mar 16, 2021
10:38AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2021   Benzinga
07:28AM EDT  Baird Upgrades Cellectis to Outperform, Raises Price Target to $39   Benzinga
Mar 4, 2021
05:22PM EST  Cellectis: Q4 Earnings Insights   Benzinga
04:44PM EST  Cellectis Q4 EPS $(0.88) Misses $(0.78) Estimate, Sales $15.63M Beat $7.64M Estimate   Benzinga
04:43PM EST  -- Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 7 leading US clinical centers   GlobeNewswire Inc
04:07AM EST  Earnings Scheduled For March 4, 2021   Benzinga
Feb 16, 2021
08:55AM EST  Cellectis, Cytovia Therapeutics Ink Gene-Edited Therapy Pact For Oncology Indications   Benzinga
01:00AM EST  Cytovia Therapeutics and Cellectis Partner to Develop   GlobeNewswire Inc
Jan 21, 2021
08:05AM EST  The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping   Benzinga
Jan 20, 2021
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
Dec 29, 2020
08:09AM EST  The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica   Benzinga
Dec 16, 2020
07:15AM EST  The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal   Benzinga
Dec 15, 2020
08:16PM EST  Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that it has withdrawn the proposed underwritten offering of American Depositary Shares (ADS) due to market conditions.   GlobeNewswire Inc
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 14, 2020
04:19PM EST  Cellectis Reports $100M ADS Follow-On Offering   Benzinga
04:19PM EST  Cellectis Announces Launch of Follow-On Offering   GlobeNewswire Inc
Dec 8, 2020
08:04AM EST  The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings   Benzinga
Dec 5, 2020
05:00PM EST  -- Cellectis Proprietary Program UCART22 was Safely Administered in BALLI-01 Phase 1 Study with No Dose-Limiting Toxicity or Evidence of Graft-Vs-Host Disease   GlobeNewswire Inc
Dec 4, 2020
08:04AM EST  The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs   Benzinga
Dec 2, 2020
07:35AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod   Benzinga
Dec 1, 2020
08:08AM EST  The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit   Benzinga
Nov 29, 2020
08:59AM EST  The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions   Benzinga
Nov 25, 2020
07:35AM EST  The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback   Benzinga
Nov 18, 2020
07:30AM EST  The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted   Benzinga
05:38AM EST  Cellectis Announced FDA Lifted Clinical Hold on MELANI-01 Study Evaluating Cellectis' Product Candidate UCARTCS1 in Multiple Myeloma   Benzinga
Nov 17, 2020
09:14PM EST  Cellectis : FDA Lifts Clinical Hold On MELANI-01 Study Evaluating Product Candidate UCARTCS1 In Multiple Myeloma   RTTNews
08:00PM EST  FDA Lifts Clinical Hold on MELANI-01 Study Evaluating   GlobeNewswire Inc
Nov 16, 2020
04:32PM EST  Cellectis Appoints Pharma HR Leader Kyung Nam-Wortman as Executive Vice President, Chief Human Resources Officer   Benzinga
04:30PM EST  Cellectis Appoints Pharma HR Leader Kyung Nam-Wortman as Executive   GlobeNewswire Inc
Nov 5, 2020
05:58PM EST  Cellectis Q3 EPS $(0.63) Misses $(0.61) Estimate, Sales $10.21M Miss $10.79M Estimate   Benzinga
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Nov 4, 2020
09:18AM EST  -- Cellectis Proprietary Program UCART22 was Safely Administered in BALLI-01 Phase 1 Study with No Dose-Limiting Toxicity or Evidence of Graft-Vs-Host Disease   GlobeNewswire Inc
Oct 21, 2020
04:30PM EDT  Cellectis to Hold Third Quarter 2020 Earnings Call on Friday,   GlobeNewswire Inc
Oct 16, 2020
08:28AM EDT  Cellectis Issues Press Release Highlighting Earlier News Of Subsidiary Calyxt's Pricing Of 3.75M Shares At $4/Share   Benzinga
08:26AM EDT  Calyxt Announces $15 Million Registered Direct Offering   GlobeNewswire Inc
Oct 15, 2020
10:36AM EDT  Why Cellectis Stock Is Trading Lower Today   Benzinga
05:22AM EDT  Baird Downgrades Cellectis to Neutral   Benzinga
Sep 2, 2020
04:57PM EDT  Cellectis to Participate in Upcoming Investor Conferences   GlobeNewswire Inc
Aug 19, 2020
09:57AM EDT  Citigroup Upgrades Cellectis to Buy, Raises Price Target to $32   Benzinga
Aug 5, 2020
05:27PM EDT  Cellectis Q2 EPS $(0.68) Beats $(0.74) Estimate, Sales $4.62M Miss $5.01M Estimate   Benzinga
04:21AM EDT  Earnings Scheduled For August 5, 2020   Benzinga
Jul 21, 2020
04:30PM EDT  Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that Steve Doares, Ph.D., joins Cellectis from Biogen as Senior Vice Presidentof US Manufacturing Manufacturing and Site Head of Raleigh manufacturing plant in NC.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC